The NexSys PCS system. [Image courtesy of Haemonetics] Haemonetics (NYSE: HAE) is reconnecting with CSL Plasma, with a new deal to supply the donation collection provider with its latest hardware. In ...
Shares in CSL, battered for most of the past two years, rallied 17.25 per cent to $157.82 as investors took a more optimistic assessment of the one-time market darling’s hopes to recapture its lost ...
Shares of Haemonetics (HAE) added ~7% in the premarket on Tuesday after the blood management solutions provider disclosed a supply agreement with Australian biopharma company CSL Limited (CSLLY) ...
After a year of impairments, revenue downgrades and the ousting of its chief executive officer, Australian plasma and vaccine specialist CSL provided signs of recovery on Tuesday. In its fiscal 2026 ...
Healthcare giant CSL says the blood-letting is over but a return to the glory days of double-digit revenue growth remains years away as it resolves problems at its Vifor kidney and iron deficiency ...
CSL underlying profit $3.14 billion, ahead of consensus Shares surge 18% in their best day since June 2001 FY27 underlying NPAT growth forecast of 5% Announces share buy-back of A$1.1 billion Aug 18 ...
„Es hat mich immer fasziniert zu sehen, wo Dinge ihren Ursprung haben“, sagte Dersch. „Es ist eine spannende Aufgabe, Fehler zu suchen und zu reparieren. Man kann das gesamte System von oben bis unten ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results